Qualigen Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
AIxCrypto Holdings reported its second quarter 2026 results, highlighting the launch of its RoboShare platform and a significant sequential decrease in operating expenses, but also substantial net losses and a depleted cash position.
AIxCrypto Holdings, Inc. has entered into a material definitive agreement for consulting services with Aibot US Operation Inc., effective July 16, 2026.
AIxCrypto Holdings, Inc. has entered into a common shares purchase agreement for a private placement offering of up to $50 million.
AIxCrypto Holdings announces a major executive leadership transition and the strategic wind-down of its legacy biotechnology business.
AIxCrypto Holdings, Inc. has entered into a note purchase agreement to sell its interest in a package of notes and related security agreements to CABG Acquisition Corp.
Faraday Future Intelligent Electric Inc. has entered into an amended securities purchase agreement with Gold King Arthur Holding Limited to raise $12 million in capital.
AIxCrypto Holdings, Inc. reported its full year 2025 financial results, detailing its strategic transformation from a biopharmaceutical company to an AI and blockchain-enabled digital infrastructure firm.
AIxCrypto Holdings, Inc. announced a strategic pivot to concentrate on Real-World Asset and Embodied AI initiatives, while discontinuing certain other projects.
AIxCrypto Holdings, Inc. announces key consulting, investment, and blockchain collaboration agreements to advance its AI and Web3 ecosystem.
AIxCrypto Holdings, Inc. announced stockholder approvals at its annual meeting and a proposed $10 million strategic investment in Faraday Future to launch its tokenized Real World Asset business.
AIxCrypto Holdings, Inc. announced the termination of Macias Gini & OConnell LLP and the engagement of HTL International, LLC as its new independent registered public accounting firm, with no reported disagreements.
AIxCrypto Holdings, Inc. received notice of non-compliance with Nasdaq's shareholder approval rule but has since remediated the deficiency and regained compliance, though it remains under a one-year panel monitor.
AIxCrypto Holdings, Inc., formerly Qualigen, officially rebranded, launched its new AIXC ticker, and unveiled a "Three Driving Forces" strategy to become a leading AI Web3 gateway.
AIxCrypto Holdings, Inc. announced key leadership changes, including the appointment of Koti Meka as Executive Director and Jie Sheng as Chairman of the Board, alongside new Audit Committee member Chad Chen.
Qualigen Therapeutics rebrands as AIxCrypto Holdings, Inc. and shifts its strategic focus from biotechnology to a Web3-driven decentralized AI technology platform following shareholder approval of key proposals.
Qualigen Therapeutics announced significant changes to its executive team, Board of Directors, and independent auditor, following a recent private placement offering.
Qualigen Therapeutics successfully closed a $41 million private placement led by Faraday Future, signaling a strategic transformation into a Web3and crypto-focused business.
Qualigen Therapeutics, Inc. announced the appointment of Kevi Chen as an independent member of its Board of Directors, effective September 26, 2025.
Qualigen Therapeutics, Inc. announced a $41 million private investment led by Faraday Future Intelligent Electric Inc. to pivot its business towards cryptocurrency and Web3, alongside significant corporate governance and management changes.
Qualigen Therapeutics, Inc. amended its secured promissory note with Marizyme, Inc., correcting the maturity date to August 21, 2026, and increasing the principal by $75,000 to $4,526,462.18.
Qualigen Therapeutics received a final extension from Nasdaq to regain compliance with the $2.5 million stockholders' equity rule, with a deadline tied to its Q3 2025 filing.
Qualigen Therapeutics, Inc. has amended its secured promissory note with Marizyme, Inc., increasing the principal to over $4.45 million and securing the debt with Marizyme's assets.
Qualigen Therapeutics regained compliance with Nasdaq's minimum stockholders' equity requirement after a $4.5 million private placement, securing an extension to maintain its listing.
Qualigen Therapeutics, Inc. announced the closing of a private placement, raising approximately $4.5 million through the sale of Series A-3 Preferred Stock to fund working capital and investor relations.
Qualigen Therapeutics, Inc. announced the grant of new patents covering its cancer drug QN-302 across 25 countries, extending protection until 2040.
Qualigen Therapeutics, Inc. announced the appointment of current independent director Robert B. Lim as the new Chair of its Audit Committee, effective immediately.
Qualigen Therapeutics received a deficiency notification from Nasdaq due to the delayed filing of its Q1 2025 report, potentially leading to delisting.
Qualigen Therapeutics has received a delisting notice from Nasdaq due to its failure to timely file its 2024 Annual Report on Form 10-K.
Qualigen Therapeutics announces its participation as the first investor in NanoSynex's 2025 bridge funding round, aimed at advancing rapid Antimicrobial Susceptibility Testing (AST) technology.
Qualigen Therapeutics has amended the terms of its Series A-2 Preferred Stock, requiring shareholder approval for any adjustments to the conversion price.